Feed aggregator

Genentech’s Tecentriq-Avastin Combo Improves Survival in Liver Cancer

Biospace news - Mon, 11/25/2019 - 02:00
Tecentriq is the company’s PD-L1 checkpoint inhibitor. Avastin is an antibody that binds to VEGF and interferes with tumor blood supply.

Clinical Catch-Up: November 18-22

Biospace news - Mon, 11/25/2019 - 02:00
As usual, it was a busy week for clinical trial updates. Here’s a look.

Public-Private Partnership Establishes New Biotech Research Center in Boston

Biospace news - Mon, 11/25/2019 - 02:00
The new facility, which could be open by the end of 2021, will be supported by Harvard University, Massachusetts Institute of Technology, GE Healthcare Life Sciences, Alexandria Real Estate Equities and FUJIFILM Diosynth Biotechnologies.

Aquestive Therapeutics Nabs Approval for Sublingual Formulation of ALS Drug

Biospace news - Mon, 11/25/2019 - 02:00
Shares of specialty pharmacy company Aquestive Therapeutics are up more than 18% in premarket trading following a late Friday afternoon approval from the U.S. FDA for Exservan, a treatment for amyotrophic lateral sclerosis.

Company Culture in Biopharma Organizations

Biospace news - Mon, 11/25/2019 - 02:00
Corporate culture is interesting because it affects almost every aspect of a business.

Ferring and Blackstone Invest $570 Million in Bladder Cancer Gene Therapy

Biospace news - Mon, 11/25/2019 - 02:00
FerGene, a Ferring subsidiary, was created to commercialize the drug in the U.S. and advance global development.

SMi's 4th Annual 3D Cell Culture

World Pharma News - Fri, 11/22/2019 - 11:00
19 - 20 February 2020, London, UK.
Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity.

AstraZeneca's Calquence Wins FDA Approval for Chronic Lymphocytic Leukemia

Biospace news - Fri, 11/22/2019 - 02:00
The latest approval for Calquence, a Bruton tyrosine kinase inhibitor, was granted under the FDA’s Real-Time Oncology Review and newly established Project Orbis programs.

Analysis Shows Pelosi Plan Could Reduce Development of 56 New Medicines Over Next 10 Years

Biospace news - Fri, 11/22/2019 - 02:00
The analysis said that if the Pelosi plan were to become the law of the land, it would cut revenues by more than half for companies with affected medicines and would also lead to a “nearly 90% reduction in new medicines” developed by those smaller U.S.-based companies.

Antibody Discovery Platform, Partnerships Help Fuel Integral Molecular's Growth

Biospace news - Fri, 11/22/2019 - 02:00
The company has doubled its headcount to about 60 employees and doubled its square-footage in the city with the 26,000 square-foot facility.

BioSpace Movers & Shakers, Nov. 22

Biospace news - Fri, 11/22/2019 - 02:00
Pharma and biotech companies strengthen their leadership teams and boards with this week's appointments.

FDA Greenlights SK Biopharma’s Xcopri for Partial-Onset Seizures

Biospace news - Fri, 11/22/2019 - 02:00
The approval marks the first time a Korean company independently brought a drug from discovery to FDA approval.

How to Host a Productive Meeting

Biospace news - Fri, 11/22/2019 - 02:00
How do you ensure the next meeting you put together is actually productive? We have a few tips.

Research Roundup: Down Syndrome Memory Pathways and More

Biospace news - Fri, 11/22/2019 - 02:00
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Two-Drug Combo Shows Promise in Treating Childhood Brain Cancers

Biospace news - Fri, 11/22/2019 - 02:00
Researchers have tested a new drug combination that shows promise for the treatment of several types of childhood brain cancers known as diffuse midline gliomas.

Career Advancement Tips for Pharmaceutical Sales

Biospace news - Fri, 11/22/2019 - 02:00
The time has arrived to begin your career journey, which includes knowing what it takes to become a successful pharma sales rep, as well as the learning about career advancement tips for pharmaceutical sales professionals.

Alexandria Real Estate Equities is Moving Forward with San Carlos Biotech Campus

Biospace news - Fri, 11/22/2019 - 02:00
The real estate developer hopes the biotech district will become the “premier destination for life science development and research” in the area.

Amgen completes acquisition of Otezla® (apremilast)

World Pharma News - Thu, 11/21/2019 - 13:00
Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis. Otezla was acquired from Celgene Corporation (NASDAQ:CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE:BMY), which was completed on Nov. 20.

Bristol-Myers Squibb completes acquisition of Celgene, creating a leading biopharma company

World Pharma News - Thu, 11/21/2019 - 11:00
Bristol-Myers Squibb Company (NYSE:BMY) has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders.

FDA Approves Second-Ever RNA Interference Drug, Alnylam’s Givlaari

Biospace news - Thu, 11/21/2019 - 02:00
The U.S. Food and Drug Administration approved Alnylam Pharmaceuticals’ Givlaari (givosiran) for acute hepatic porphyria.